Skip to main content

Lobbying activity

Who's lobbying Congress, for whom, and on what, from federal Lobbying Disclosure Act filings. Covers both chambers, synced daily. 139 filings

Top spenders & firms Spend by issue Political contributions Revolving door

  Showing filings that named HR 1672. Clear
Clear
Q2
TIBER CREEK GROUP for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Medicare/Medicaid, Health Issues, Trade (domestic/foreign)
View → Q2
IONIS PHARMACEUTICALS, INC. for IONIS PHARMACEUTICALS, INC.
2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate
Medicare/Medicaid, Taxation/Internal Revenue Code, Health Issues
View → Q2
TODD STRATEGY GROUP for NOVARTIS, INC.
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Trade (domestic/foreign)
View → Q2
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS for NOVARTIS
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income
Trade (domestic/foreign), Health Issues
View → Q2
TROUTMAN STRATEGIES for THE MENDED HEARTS, INC.
2nd Quarter (Apr 1 - June 30) 2026 · Georgia · House · Senate · $60,000.00 income
Health Issues
View → Q2
HEALTHCARE INSTITUTE OF NEW JERSEY for HEALTHCARE INSTITUTE OF NEW JERSEY
2nd Quarter (Apr 1 - June 30) 2026 · New Jersey · House · Senate
Health Issues
View → Q2
LMH STRATEGIC SOLUTIONS for IONIS PHARMACEUTICALS, INC.
2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $30,000.00 income
Health Issues
View → Q2
LMH STRATEGIC SOLUTIONS for ALNYLAM PHARMACEUTICALS, INC.
2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $50,000.00 income
Medicare/Medicaid
View → Q1
BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · $90,000.00 income
Health Issues
View → Q1
AVENUE SOLUTIONS for GENENTECH USA, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income
Medicare/Medicaid, Health Issues
View → Q1
TODD STRATEGY GROUP for NOVARTIS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid, Trade (domestic/foreign)
View → Q1
AMGEN, INC. for AMGEN INC
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Copyright/Patent/Trademark
View → Q1
TODD STRATEGY GROUP for ASTRAZENECA PHARMACEUTICALS LP
1st Quarter (Jan 1 - Mar 31) 2026 · Delaware · House · Senate · $80,000.00 income
Medicare/Medicaid, Health Issues
View → Q1
TODD STRATEGY GROUP for ALNYLAM PHARMACEUTICALS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income
Medicare/Medicaid
View → Q1
SPLITOAK STRATEGIES LLC for ALNYLAM PHARMACEUTICALS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income
Medicare/Medicaid
View → Q1
BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Budget/Appropriations, Copyright/Patent/Trademark, Health Issues, Homeland Security
View → Q1
TIBER CREEK GROUP for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income
Medicare/Medicaid, Health Issues, Trade (domestic/foreign)
View → Q1
ALNYLAM PHARMACEUTICALS, INC. for ALNYLAM PHARMACEUTICALS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate
Medicare/Medicaid, Trade (domestic/foreign), Pharmacy
View → Q1
DLA PIPER LLP (US) for NOVARTIS
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income
Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Trade (domestic/foreign), Health Issues
View → Q1
BGR GOVERNMENT AFFAIRS for NOVARTIS
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income
Health Issues, Medicare/Medicaid
View → Q1
NOVARTIS for NOVARTIS
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Labor Issues/Antitrust/Workplace, Budget/Appropriations, Copyright/Patent/Trademark, Health Issues
View → Q1
PERSONALIZED MEDICINE COALITION for PERSONALIZED MEDICINE COALITION
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate
Budget/Appropriations, Health Issues
View → Q1
TROUTMAN STRATEGIES for THE MENDED HEARTS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Georgia · House · Senate · $60,000.00 income
Health Issues
View → Q1
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS for NOVARTIS
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income
Trade (domestic/foreign), Health Issues
View → Q1
FORBES-TATE for IONIS PHARMACEUTICAL, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $30,000.00 income
Health Issues, Medicare/Medicaid
View →
Page 1 of 6 Next

Source: federal Lobbying Disclosure Act filings. A filing's bill references are parsed from its activity descriptions, so a bill page shows the filings that named it.

Report a problem